RecruitingNot ApplicableNCT05345158

R-RPLND as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma

Robotic Retroperitoneal Lymph Node Dissection (R-RPLND) as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma


Sponsor

University Health Network, Toronto

Enrollment

25 participants

Start Date

Feb 23, 2022

Study Type

INTERVENTIONAL

Conditions

Summary

This study will investigate the safety and efficacy of using robotic retroperitoneal lymph node dissection (R-RPLND), a minimally invasive surgical approach, as the first-line of treatment for stage IIA/B (or equivalent) seminoma patients. R-RPLND will be trialed as an alternative to chemotherapy, radiation therapy (for seminoma patients) and open RPLND in this study.


Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether robotic-assisted surgery to remove lymph nodes in the back of the abdomen (R-RPLND) can effectively treat testicular seminoma (a type of testicular cancer) that has spread to nearby lymph nodes, as an alternative to radiation or chemotherapy. **You may be eligible if...** - You have testicular seminoma confirmed by pathology with clean surgical margins after orchiectomy (testicle removal) - Lymph nodes in your retroperitoneum (back of the abdomen) are enlarged, with at least one node ≤5cm - Your chest CT shows no spread to the lungs or elsewhere - Your tumor markers (AFP and β-hCG) are within acceptable limits - You have not had surgery for this cancer before, or you relapsed after watchful waiting **You may NOT be eligible if...** - Your lymph nodes are larger than 5cm - Cancer has spread to the chest or distant organs - Your tumor markers significantly exceed normal limits Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURERobotic Retroperitoneal Lymph Node Dissection (RPLND)

Robotic RPLND performed using the DaVinci robotic surgical system.


Locations(1)

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05345158